Conditions: Over-Active Bladder
Keywords: Urination Disorder Overactive Bladder Prostate Cancer Radiation Vesicare
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 8
Healthy volunteers: yes

Brief summary:
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.

Detailed description:
This is a randomized double blind placebo controlled flexible dose 12 week study. Following screening, subjects will receive their first dose of study medication following completion of AUASS questionnaire on the first day of radiation treatment (baseline) and will continue for twelve weeks. Subjects will be started on 5 mg of study medication. The AUASS will be completed at baseline, weeks 4, 8 and 12. A 16 week visit conducted over a phone interview.

Arms:
arm 1: Solifenacin succinate, 5mg or 10 mg once daily arm 2: Drug: Placebo oral

Interventions: intervention 1: Solifenacin succinate intervention 2: Placebo
Intervention descriptions: intervention 1: IGRT with VESIcare intervention 2: IGRT with placebo

Protocol document: